12 recruiting, 4 unknown, 3 not yet recruiting, 2 terminated. 14 Phase 1, 10 Phase 2, 2 Early Phase 1, 1 Phase 3.
Follow Relapsed Non-Hodgkin Lymphoma: new trials by email Literature Review of Relapsed Non-Hodgkin Lymphoma trials Research Report on Relapsed Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell | Phase 3 | Recruiting | Lyell Immunopharma, Inc. | 400 | 2026-01-12 | 2026-08-04 |
| Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Homoharringtonine, BCL-2 inhibitor, CD20 Antibody - Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 62 | 2025-09-08 | 2025-09-08 |
| Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3 - Leukemia, High Risk Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 100 | 2025-03-21 | 2026-04-15 |
| A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL ATRA, Pembrolizumab - Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Rita Assi | 24 | 2024-11-18 | 2026-02-10 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| Emapalumab Prevention of CAR-T Cell Associated Toxicities Emapalumab, Cyclophosphamide, Fludarabine Phosphate - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 28 | 2024-09-18 | 2026-10-06 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma SIRPant-M, External-beam radiotherapy (XRT) - Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | Recruiting | SIRPant Immunotherapeutics, Inc. | 24 | 2024-01-17 | 2024-12-20 |
| First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma ARI0003 - Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Early Phase 1 | Not yet recruiting | Fundacion Clinic per a la Recerca Biomédica | 40 | 2024-01-15 | 2023-10-26 |
| Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma Chidamide combined with Linperlisib - Follicular Lymphoma, Refractory B-Cell Lymphoma | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 33 | 2023-11-22 | 2025-02-19 |
| Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 27 | 2023-11-08 | 2026-03-31 |
| CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine - Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 24 | 2023-10-26 | 2026-10-09 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research Relapsed Non-Hodgkin Lymphoma | Unknown | Ruijin Hospital | 22 | 2023-10-01 | 2023-09-22 | |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies BGB-21447 - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | BeOne Medicines | 51 | 2023-06-20 | 2026-07-14 |
| Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Lyell Immunopharma, Inc. | 270 | 2023-05-09 | 2026-08-25 |
| Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA) no intervention (observational study) - Diffuse Large B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 300 | 2023-04-01 | 2023-02-28 | |
| Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma Bridging radiation therapy, Liso-cel, Post-infusion radiation - DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | University of Nebraska | 33 | 2023-03-21 | 2026-10-08 |
| ThisCART19A for B-NHL Relapsed After Auto-CAR T ThisCART19A with Dose Level 1, ThisCART19A with Dose Level 2 - CAR, B Cell Lymphoma | Phase 1 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2022-12-01 | 2023-01-19 |
| Long-Term Follow-up Study Caribou-sponsored investigational therapy - Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma | Enrolling by invitation | Caribou Biosciences, Inc. | 150 | 2022-03-16 | 2026-03-12 |
Showing 20 of 24. Sign in to see all of them.
Lymphoma, Non-Hodgkin (24) · Lymphoma, B-Cell (9) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Follicular (7) · Lymphoma (4) · Hodgkin Disease (3) · Lymphoma, B-Cell, Marginal Zone (3) · Dendritic Cell Sarcoma, Interdigitating (2) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Mantle-Cell (2) · Multiple Myeloma (2) · Anemia, Refractory, with Excess of Blasts (1) · Bone Marrow Failure Disorders (1)
Hemic and Lymphatic Diseases (24) · Immunoproliferative Disorders (24) · Lymphatic Diseases (24) · Lymphoproliferative Disorders (24) · Neoplasms by Histologic Type (24) · Immune System Diseases (23) · Neoplasms (23) · Lymphoma (20) · Hematologic Diseases (6) · Lymphoma, B-Cell (4) · Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Hemorrhagic Disorders (3) · Hemostatic Disorders (3) · Leukemia (3)
Cyclophosphamide (5) · fludarabine (3) · fludarabine phosphate (3) · Immunotherapy, Adoptive (2) · Rituximab (2) · axicabtagene ciloleucel (2) · pembrolizumab (2) · Antibodies, Monoclonal (1) · Automobiles (1) · Clinical Trials, Phase I as Topic (1) · Cord Blood Stem Cell Transplantation (1) · Cyclosporine (1) · Dexamethasone (1) · Emapalumab (1) · Glucocorticoids (1)
Lyell Immunopharma, Inc. (2) · Marcela V. Maus, M.D.,Ph.D. (2) · BeOne Medicines (1) · Caribou Biosciences, Inc. (1) · Case Comprehensive Cancer Center (1) · Children's Hospital of Philadelphia (1) · Chinese PLA General Hospital (1) · Chongqing Precision Biotech Co., Ltd (1) · Estrella Immunopharma, Inc. (1) · First Affiliated Hospital of Zhejiang University (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fundacion Clinic per a la Recerca Biomédica (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Indapta Therapeutics, INC. (1) · NYU Langone Health (1)
United States (16) · China (6) · Australia (2) · Italy (1) · New Zealand (1) · Spain (1)
Matthew Frigault, MD (2) · Catherine Diefenbach, MD (1) · Christopher R D'Angelo, MD (1) · Jelle Kijlstra, MD, MBA (1) · Jianfeng Bi, M.D (1) · Laura A Johnson, PhD (1) · Leland Metheny, MD (1) · Michael Jain, MD, PhD (1) · Pei Wang, PhD (1) · Rita Assi, MD (1) · Stefan Hohaus, MD (1) · Timothy Olson, MD, PhD (1)
2025 (1), P30CA043703 (1)